Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs

Xu-chen ZHOU; Rong-chong HUANG; Bo ZHANG; Da YIN; Bin LIANG; Shao-peng WANG; Qi-gang GUAN; Xi-zhuo SUN; Zhi-lin MIAO; Xue-zhi HE; Feng-tong HAN; Ying CHENG; Li ZHANG; Ding-yin ZENG.
Chinese Medical Journal ; (24): 2405-2409, 2010.
Artículo en Inglés | WPRIM | ID: wpr-237441

Documentos relacionados

  1. Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1ß-induced coronary artery in-stent restenosis in pigs.
  2. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.
  3. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial.
  4. Nanospheres encapsulated everolimus delivery into arterial wall-the tissue pharmacokinetics and vascular response experimental study.
  5. Rapamycin and Paclitaxel Affect Human Aortic Smooth Muscle Cells-Derived Foam Cells Viability and Proliferation.
  6. Design, manufacture and initial tests of a drug-eluting coronary stent.
  7. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
  8. Optical coherence tomography assessment of acute thrombogenicity at bifurcation sites using different stenting techniques: A porcine arteriovenous shunt study.
  9. Modeling Dual Drug Delivery from Eluting Stents: The Influence of Non-Linear Binding Competition and Non-Uniform Drug Loading.
  10. [Stents coated with sirolimus and anti-CD34 antibody can optimize the performance of sirolimus-eluting stents].